Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

G2D2

- PMLiVE

Eisai names new US financial head

Barry Lederman joins as chief financial officer

- PMLiVE

UK’s MRC launches public-private push on dementia research

AstraZeneca, GSK and J&J will support £16m programme

- PMLiVE

Eisai resubmits Fycompa to G-BA for pricing assessment

But German distribution of epilepsy drug remains on hold until reimbursement settled

- PMLiVE

Teva backs UK’s dementia drive with $21m investment

Pharma company will support National Institute for Health Research

Biogen Idec building

Eisai and Biogen partner on Alzheimer’s

Will co-develop two drug candidates

- PMLiVE

Germany looks again at Fycompa pricing

Eisai's epilepsy drug could be re-entered onto market

- PMLiVE

G8 sets 2025 target for effective dementia treatment

World leaders pledge more research funding

- PMLiVE

Dementia map reveals extent of under-diagnosis

Less than half of patients in England are diagnosed

- PMLiVE

FDA approves Alzheimer’s diagnostic drug

GE Healthcare's Vizamyl to compete with Lilly's Amyvid

- PMLiVE

Eisai doubles Belviq’s US sales force

Will take on more than 200 new contact sales reps to promote obesity drug

- PMLiVE

Eisai expands in Europe with new Belgium business

Will coordinate local reimbursement for cancer drug Halaven

- PMLiVE

Eisai launches Halaven in Russia

Expands market reach of its breast cancer drug to cover emerging market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links